Treatment of friedreich's ataxia using histone deacetylase inhibitors

US9957225B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9957225-B2
Application numberUS-201414480899-A
CountryUS
Kind codeB2
Filing dateSep 9, 2014
Priority dateNov 11, 2005
Publication dateMay 1, 2018
Grant dateMay 1, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides methods of treating Friedreich's ataxia and other neurodegenerative or neuromuscular conditions using histone deacetylase inhibitors.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of treating, or delaying the onset of Huntington's disease in a mammal comprising administering to the mammal a compound of formula I in an amount effective to alter the level of histone acetylation in the mammal and increase frataxin mRNA in lymphocytes from Friedreich's ataxia patients, wherein formula I is: wherein: n is 2 to about 10; R 1 is aryl or heteroaryl; R 2 is aryl or heteroaryl; R a and R b are each independently H, alkyl, aryl, heteroaryl, or a nitrogen protecting group; wherein any alkyl, aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halo, alkyl, trifluoromethyl, alkoxy, aryl, and NR c R d ; wherein R c and R d are each independently hydrogen, alkyl, or C(═O)OR e wherein R e is H or alkyl; or a salt thereof. 2. The method of claim 1 , further comprising identifying the mammal as one suffering from, or at risk for, Huntington's disease. 3. The method of claim 1 , wherein the mammal is a human. 4. The method of claim 1 , wherein the compound of formula I has a structure selected from the group consisting of: a salt of a compound thereof; and any combination thereof.

Assignees

Inventors

Classifications

  • having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton · CPC title

  • having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings · CPC title

  • from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines · CPC title

  • having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

  • Preparation of carboxylic acid amides · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9957225B2 cover?
The invention provides methods of treating Friedreich's ataxia and other neurodegenerative or neuromuscular conditions using histone deacetylase inhibitors.
Who is the assignee on this patent?
Scripps Research Inst
What technology area does this patent fall under?
Primary CPC classification C07D213/75. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).